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Main text 
The risk of developing renal cancers is reportedly 3−5% among patients with 
end-stage renal disease pre- and post-transplantation, which is 100-fold higher 
than that among the general population (1). Immunosuppressive therapies, which 
are administered to prevent graft rejection, increase the risk of developing 
cancers or accelerate tumor cell growth (2). Currently, the treatment strategy for 
metastatic renal cell carcinoma (mRCC) consists of molecular-targeted therapy. 
Sorafenib is one of first-line tyrosine kinase inhibitors, and its efficacy has been 
demonstrated in a previous clinical trial (3). However, clinical information on the 
use of sorafenib in patients with renal dysfunction, such as those with end-stage 
renal disease or those who have undergone kidney transplantation, has been 
limited, because such patients were excluded from the aforementioned trial. We 
previously reported the efficacy and safety of sorafenib in 20 patients with mRCC 
undergoing dialysis therapy (1). Our former study indicated that sorafenib 
treatment seemed feasible (median time to progression: 6.3 months; overall 
survival: 14.2 months), although careful monitoring of severe adverse events 
(AEs) was required (4 of 20 patients [20.0%] discontinued treatment because 
of ≥grade 3 AEs). Thus, we believe that sorafenib treatment is effective for 
patients with renal dysfunction. Herein, we describe our single-center experience 
with first-line sorafenib treatment in 4 kidney transplant patients with mRCC.  
Patient characteristics and outcomes are shown in Table 1. All cancers 
originated from native kidneys. Three patients were pathologically diagnosed as 
having clear-cell carcinoma. All patients received the same immunosuppressive 
regimen, including tacrolimus, mycophenolate mofetil, and methylprednisolone at 
4 
 
the time of diagnosis. Conversion to a different regimen (i.e., mycophenolate 
mofetil to everolimus) was performed in 3 patients. All patients experienced 
disease progression and died of the cancers. The median times to disease 
progression and to death were 8.98 and 15.1 months, respectively. AEs were 
observed in 3 patients; ≥grade 3 AEs were observed in 1 patient (25%). During 
treatment, graft function was stable, and no patient required a major adjustment 
in the dose of tacrolimus.  
Previous studies have indicated that the median progression-free survival 
ranges from 5–9 months (3, 4), and the median overall survival is 12.5 months in 
the general population (4). Thus, an equivalent effect of prolonging survival in 
kidney transplant patients was shown in this study. However, physicians need to 
pay attention to frequent AEs in these patients compared to the general 
population (3, 4). Moreover, sorafenib treatment had a similar efficacy and toxicity 
in kidney transplant patients compared to patients with hemodialysis (1). 
Finally, the present study’s findings may suggest that sorafenib does not affect 
immunosuppression, because we did not need to modify the dose of tacrolimus. 
This may be because sorafenib, which is a multi-targeted tyrosine kinase inhibitor 
of Raf, the vascular endothelial growth factor receptor, and platlet-derived growth 
factor receptor, is not associated with the mechanism of immunosuppression 
caused by tacrolimus. However, there may be a possible pharmacokinetic 
correlation between the two different agents, thus further investigations are 
needed.  
In summary, first-line sorafenib treatment seems feasible in kidney transplant 
patients with mRCC; nevertheless, careful monitoring for AEs is required. 
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Table 1: Patients’ characteristics and outcomes 
Case Sex Dialysis 
duration 
before KTx 
(month) 
Immunosuppr
essive agents 
at diagnosis 
mRCC 
Age at 
diagnosis 
(year) 
MSKCC  Pathology  Time from 
KTx to 
diagnosis 
(month) 
Initial/mai
ntenance 
dose (mg) 
Conversion  Time to disease 
progression/death 
(month) 
AEs FK dose at 
treatment 
initiation/end 
(mg) 
1 Male 192 FK, MMF, MP 55 Intermediate CCC 26.1 400/800 MMF to EVL 6.67/15.6 None 1/1 
2 Male 48 FK, MMF, MP 73 Intermediate CCC 126.8 400/400 MMF to EVL 11.3/14.6 Anemia G3 N/A 
3 Male 192 FK, MMF, MP 52 Intermediate CCC with 
sarcomatoid  
67.2 600/600 None 3.42/6/67 Gastrointestinal 
disorder G2 
1/1 
4 Male 57 FK, MMF, MP 70 Favorable CCC 37.6 400/600 MMF to EVL 23.1/29.1 Gastrointestinal 
disorder G2 
2/1 
Mean 
(median, 
range) 
 122,3 
(124.5, 48.0 
– 192) 
 62.5 
(62.5, 52 
– 73) 
  64.4 (52.4, 
26.1 – 
126.8) 
  11.1 (8.98, 3.42 – 
23.1)/16.5 (15.1, 
6.67 – 29.1) 
  
KTx, kidney transplantation; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; AEs, adverse events; FK, tacrolimus; MMF, 
mycophenolate mofetil; MP, methylprednisolone; CCC, clear-cell carcinoma; EVL, everolimus; G, grade; N/A, not applicable;  
 
